
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past few days:
Amgen’s 2010 sales, earnings flat
Amgen (NSDQ:AMGN) posted profits of $1.02 billion, or $1.08 per diluted share, on sales of $3.84 billion during the three months ended Dec. 31. That compares with profits of $1.10 billion, or 92 cents per diluted share, on sales of $$3.81 billion during Q4 2009. For the full year, Amgen’s profits were $4.63 billion, or $4.79 per diluted share, on sales of $15.05 billion — increases of 0.5 percent and 2.8 percent, respectively.
Read more
Rochester Medical’s Q1 sales rise 7 percent, net losses stay level
Rochester Medical Corp. (NSDQ:ROCM) posted losses of $169,000, or 10 cents per diluted share, on sales of $10.9 million during the three months ended Dec. 31. That compares with losses of $169,000, or 10 cents per diluted share, on sales of $10.2 million during Q1 2010.
Read more
Waters Corp. logs strong Q4, 2010 results
Waters Corp. (NYSE:WAT) posted profits of $126.6 million, or $1.36 per diluted share, on sales of $483.6 million during the three months ended Dec. 31. That compares with profits of $104.1 million, or $1.08 per diluted share, on sales of $428.8 million during Q4 2009. For the full year, profits were $381.8 million, or $4.06 per diluted share, on sales of $1.64 billion — increases of 21.6 percent and 9.7 percent, respectively.
Read more
Quest Diagnostics posts sales earnings declines for the fourth quarter and 2010
Quest Diagnostics Inc. (NYSE:DGX) posted profits of $$165.7 million, or 96 cents per diluted share, on sales of $1.82 billion during the three months ended Dec. 31. That compares with profits of $181.6 million, or 98 cents per diluted share, on sales of $1.85 billion during Q4 2009. For the full year, profits were $720.9 million, or $4.05 per diluted share, on sales of $7.37 billion — declines of 1.1 percent and 1.2 percent, respectively.
Read more
Centinel Spine touts record Q4 results
Centinel Spine Inc. announced a record 32.5 percent revenue increase during the 2010 fourth quarter compared with the same period in 2009. Sales rose 41.8 percent compared with the third quarter last year.
Read more
Clinipace doubles 2010 revenues
CRO Clinipace Worldwide closed its best year to date, doubling 2010 revenues from 2009 to 2010 and boosting its top line more than 800 percent since 2008.
Read more